Drugs / Evalstotug
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05180799 | Aug 2022 → Mar 2025 overdue | melanoma, non-small cell lung carcinoma | BioAtla, Inc. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05271604 | Dec 2022 → Sep 2025 | head and neck squamous cell carcinoma, metastatic malignant neoplasm | BioAtla, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-07-25 | BioAtla, Inc. | Results BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day bioatla.com ↗
“Every one of my patients who has received evalstotug has experienced clinical benefit, including an advanced melanoma patient who achieved no evidence of disease, which I consider a clinical complete response,” said Dr. Mangla. |
| 2024-05-23 | BioAtla, Inc. | Results BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting bioatla.com ↗
Multiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients receiving evalstotug |
| 2023-12-13 | BioAtla, Inc. | Results BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types bioatla.com ↗
We observed confirmed clinical responses and prolonged stable disease among 18 patients treated with BA3071 in combination with PD-1. |
All press releases naming this drug 5 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Evalstotug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05271604 ↗ |
| Known as | BA3071 | “Biological: Evalstotug (BA3071)” NCT05271604 ↗ |
| Action | Inhibit | “Conditionally active biologic anti-CTLA-4 checkpoint blockade antibody” NCT05271604 ↗ |
| Modality | Monoclonal antibody | “Conditionally active biologic (CAB) antibody” NCT05180799 ↗ |